JOHN KIRKWOOD to Cytokines
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Cytokines.
Connection Strength
0.418
-
Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2331s-2336s.
Score: 0.159
-
Interferon alpha in combination with other biologics: the scientific rationale. Br J Haematol. 1991 Oct; 79 Suppl 1:78-80.
Score: 0.058
-
Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. J Transl Med. 2009 Jul 29; 7:68.
Score: 0.050
-
Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res. 2007 Apr 15; 13(8):2422-8.
Score: 0.043
-
Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomes. Front Immunol. 2023; 14:1171978.
Score: 0.033
-
Biologic therapy. Clin Plast Surg. 2000 Oct; 27(4):643-65.
Score: 0.027
-
CD226 opposes TIGIT to disrupt Tregs in melanoma. JCI Insight. 2018 07 26; 3(14).
Score: 0.023
-
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol. 2009 May 01; 182(9):5240-9.
Score: 0.012
-
Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol. 2008 Mar 01; 180(5):2967-80.
Score: 0.011